2017
DOI: 10.1007/s12471-017-1002-3
|View full text |Cite
|
Sign up to set email alerts
|

Management of elderly patients with a non-ST-segment-elevation acute coronary syndrome

Abstract: Elderly patients with an acute coronary syndrome are underrepresented in randomised controlled trials. Neither the European Society of Cardiology nor the American Heart Association/American College of Cardiology acute coronary syndrome guidelines provide specific recommendations for elderly patients. However, elderly patients are at higher thrombotic and bleeding risk compared with younger patients leading to difficulties in choosing the optimal treatment. In this review, we discuss the uncertainties we encoun… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0
1

Year Published

2018
2018
2022
2022

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(4 citation statements)
references
References 52 publications
0
3
0
1
Order By: Relevance
“…Our study included 305 patients with NSTEMI whose mean age was 70.62 ± 11.05 years CI 95% (69.28 -71.77) confirming the presence of non-ST-segment elevation myocardial infarction at older age [7][8][9][10][11] being more than 5 years old for women (73.36 ± 10.05 years) than for males (68.3 ± 11.32 years).…”
Section: Resultsmentioning
confidence: 88%
“…Our study included 305 patients with NSTEMI whose mean age was 70.62 ± 11.05 years CI 95% (69.28 -71.77) confirming the presence of non-ST-segment elevation myocardial infarction at older age [7][8][9][10][11] being more than 5 years old for women (73.36 ± 10.05 years) than for males (68.3 ± 11.32 years).…”
Section: Resultsmentioning
confidence: 88%
“…Although PCI can be used to immediately restart coronary circulation, it may also result in complications, particularly in frail older adult patients with many comorbidities (Gimbel & ten Berg, 2017; Kumar et al, 2020), and this is the reason such patients sometimes decline PCI (Negers et al, 2017; O’Neill et al, 2016). Thus, risk assessment—accounting for age, symptoms, vital signs, biomarkers, and electrocardiogram presentation—is always the first step toward assessing global risk in patients with NSTEMI (Gimbel & ten Berg, 2017; Y. H. Li et al, 2018).…”
Section: Analysis Of the Problemmentioning
confidence: 99%
“…В исследовании M. E. Gimbel и соавт. установлено преимущество введения фондапаринукса и болюсного нефракционированного гепарина у пациентов с ОКСбпST старшего возраста, подвергающихся ЧКВ [23]. По мнению S. Yusuf и соавт., фондапаринукс (2,5 мг / сут) также является антикоагулянтом выбора у пожилых пациентов с ОКСбпST, которым показано консервативное лечение, в то время как эноксапарин требует более тщательного и осторожного титрования дозы [24].…”
Section: антикоагулянтная терапияunclassified